Reducing breast symptoms after second trimester abortion
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial
PHASE4 · Northwestern University · NCT06123026
This study is testing if a medication called cabergoline can help reduce breast symptoms like lactation and engorgement in people who have a second trimester abortion.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | Northwestern University (other) |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT06123026 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of cabergoline in reducing breast symptoms such as lactation and engorgement in individuals who undergo a second trimester abortion between 16 and 20 weeks of gestation. Participants will be randomly assigned to receive either cabergoline or a placebo immediately following their procedure. The study will compare the breast symptoms experienced by both groups to determine if cabergoline significantly alleviates these symptoms compared to the placebo. This research is crucial for improving post-abortion care and comfort for patients.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 to 50 seeking termination of pregnancy between 16 and 20 weeks of gestation.
Not a fit: Patients outside the age range of 18 to 50 or those with specific medical conditions such as uncontrolled hypertension or allergies to the study medication may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new option for managing breast symptoms after second trimester abortions, enhancing patient comfort and care.
How similar studies have performed: While this specific approach may be novel, similar studies on lactation suppression have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises * ages 18 to 50 * con provide informed consent in English Exclusion Criteria: * Age under 18 or above 50 * gestational ages before 16 weeks 0 days or after 20 weeks 0 days * unable to provide written consent in English * hypertensive disorder * uncontrolled hypertension or known hypersensitivity to ergot derivatives * History of cardiac valvular disorders * history of pulmonary fibrosis * documented bipolar schizophrenia * documented allergy to medication, including lactose intolerance (placebo pill involves lactose)
Where this trial is running
Chicago, Illinois
- Northwestern Medical Center — Chicago, Illinois, United States (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lactation Suppressed, Second Trimester Abortion